Cost–effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma
| Autor: | Lisa M. Meckley, Kelly M Shriner, Michael J. Cangelosi, Ayanna M. Anene, Jesse D. Ortendahl, Tanya G. K. Bentley, John Fox |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Combination therapy Cost effectiveness Cost-Benefit Analysis Severity of Illness Index Quality of life Bronchoscopy medicine Humans Pharmacology (medical) Intensive care medicine Adverse effect Asthma Bronchial thermoplasty medicine.diagnostic_test business.industry Health Policy Severe persistent asthma General Medicine medicine.disease Markov Chains Models Economic Catheter Ablation Quality of Life Quality-Adjusted Life Years business |
| Zdroj: | Expert Review of Pharmacoeconomics & Outcomes Research. 15:357-364 |
| ISSN: | 1744-8379 1473-7167 |
| DOI: | 10.1586/14737167.2015.978292 |
| Popis: | We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations.We conducted a model-based cost-effectiveness analysis assessing 5-year healthcare utilization, patient quality of life and adverse events.We utilized Markov modeling to estimate the costs and quality-of-life impact of BT compared with high-dose combination therapy among poorly controlled, severe, persistent asthma patients: those requiring high-dose combination therapy and having experienced an asthma exacerbation-related ER visit in the past year.The cost-effectiveness of BT was US$5495 per quality-adjusted life year; and approximately 22% of sensitivity analysis iterations estimated BT to reduce costs and increase quality of life.BT is a cost-effective treatment option for patients with poorly controlled, severe, persistent asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|